Product Complaints Analyst 2

Illumina's shares fell after its third-quarter results, trading at $235.59 against $290.06 before the earnings. Revenue rose 7.6% year on year to $1.17 billion, beating analyst estimates of $1.15 billion, while adjusted EPS of $1.44 topped the $1.36 forecast. Chief executive officer Jacob Thaysen credited strong clinical sequencing demand and robust NovaSeq X placements. Research and applied markets stayed weak. Operating margin reached 26.2%, up from 20.9% a year earlier. The company raised its full-year revenue guidance to $4.65 billion at the midpoint from $4.62 billion, and adjusted EPS guidance to $5.43. Analysts asked whether NovaSeq X demand was pulled forward. Thaysen said it was not, and that placements reflect normal business. He and chief financial officer Ankur Dhingra said AI-driven products such as BioInsight could add visibly to growth by 2027.

54,741 Illumina, Inc. $ILMN shares bought by international Assets Investment Management LLC. International Assets Investment Management LLC grew its holdings in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 10,608.7% in the third quarter, Holdings Channel.com reports. The firm owned 55,257 shares of the life sciences company's stock after purchasing an additional 54,741 shares during the period. International Assets Investment Management LLC's holdings in Illumina were worth $15,123,000 as of its most recent SEC filing. A number of other hedge funds also recently modified their holdings of ILMN. BlackRock Inc. purchased a new position in shares of Illumina during the second quarter valued at $3,374,423,000. Plato Investment Management Ltd acquired a new position in Illumina during the second quarter valued at $948,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in Illumina in the 2nd quarter worth about $30,501,000. Edmond DE Rothschild Holding S.A. purchased a new stake in Illumina in the 2nd quarter worth about $129,792,000. Finally, OVERSEA CHINESE BANKING Corp Ltd purchased a new stake in Illumina in the 2nd quarter worth about $6,711,000. Hedge funds and other institutional investors own 89.42% of the company's stock. Wall street analysts forecast growth. A number of equities research analysts have commented on the company. Canaccord Genuity Group raised their price objective on Illumina from $205.00 to $300.00 and gave the stock a "hold" rating in a research report on Monday, October 19th. Stifel Nicolaus upped their target price on Illumina from $155.00 to $225.00 and gave the company a "buy" rating in a report on Friday, July 31st. TD Cowen increased their price target on shares of Illumina from $210.00 to $270.00 and gave the stock a "hold" rating in a research report on Tuesday, October 13th. Barclays increased their price target on shares of Illumina from $160.00 to $200.00 and gave the stock an "underweight" rating in a research report on Wednesday, October 7th. Finally, JPMorgan Chase & Co. decreased their price target on shares of Illumina from $320.00 to $300.00 and set an "overweight" rating for the company in a report on Friday. Nine investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and three have assigned a Sell rating to the company's stock. According to MarketBeat.com, Illumina has an average rating of "Hold" and a consensus target price of $238.53. Illumina news roundup. Here are the key news stories impacting Illumina this week: * Adjusted earnings exceeded expectations. Illumina reported third-quarter adjusted EPS of $1.44, above the $1.36 consensus estimate, while revenue increased 4.2% year over year to approximately $1.13 billion. * Full-year guidance was raised. Management increased its 2026 outlook, with revenue guidance of roughly $4.65 billion at the midpoint, supported by clinical sequencing demand and continued adoption of the NovaSeq X platform. * Long-term industry demand remains favorable. Recent market reports point to strong growth in clinical genomics, sequencing-as-a-service, population screening, and AI-enabled genomic analysis - markets in which Illumina is a major participant. These reports are industry forecasts rather than new company contracts or financial commitments. * Analyst sentiment became more cautious. JPMorgan reduced its price target from $320 to $300, while Robert W. Baird maintained a Hold rating. The target cut suggests less near-term upside following Illumina's substantial prior rally. * Revenue performance disappointed investors. Although earnings surpassed estimates, quarterly revenue was below consensus in several reports, highlighting softer demand than expected and limiting the impact of the profit beat. * China exposure, tariffs, and business mix remain concerns. Investors are worried about China-related revenue challenges, tariff uncertainty, research-market weakness, and pricing pressure. A broader pullback in AI-linked technology stocks also hurt sentiment toward Illumina. Insiders place their bets. In other news, Director Keith Meister sold 457,858 shares of the firm's stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $200.10, for a total transaction of $91,617,385.80. Following the completion of the sale, the director directly owned 2,372,694 shares of the company's stock, valued at $474,776,069.40. This trade represents a 16.18% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Over the last quarter, insiders sold 2,061,235 shares of company stock valued at $436,356,102. Corporate insiders own 2.90% of the company's stock. Illumina trading down 18.6%. NASDAQ ILMN opened at $235.99 on Friday. The company has a current ratio of 1.80, a quick ratio of 1.40 and a debt-to-equity ratio of 0.53. Illumina, Inc. has a 1-year low of $106.12 and a 1-year high of $309.35. The firm's fifty day simple moving average is $249.30 and its 200-day simple moving average is $176.18. The company has a market capitalization of $35.63 billion, a PE ratio of 40.62, a price-to-earnings-growth ratio of 3.34 and a beta of 1.41. Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings data on Thursday, October 29th. The life sciences company reported $1.62 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.36 by $0.26. The firm had revenue of $1.17 billion during the quarter, compared to analysts' expectations of $1.15 billion. Illumina had a return on equity of 29.41% and a net margin of 19.72%. The business's revenue for the quarter was up 4.2% on a year-over-year basis. During the same quarter last year, the firm earned $1.34 earnings per share. As a group, sell-side analysts anticipate that Illumina, Inc. will post 5.43 earnings per share for the current fiscal year. Illumina company profile. Illumina, Inc is a biotechnology company that develops and manufactures genomics and genetic-analysis technologies. Its products are used to study DNA and RNA in applications including biomedical research, clinical testing, pharmaceutical development, reproductive health, oncology and population genomics. The company's offerings include next-generation sequencing systems, consumable flow cells and reagent kits, microarrays, and genomic data-analysis software. Its sequencing portfolio includes instruments such as the NovaSeq, NextSeq, MiSeq and iSeq platforms, while its informatics products include the DRAGEN platform, which supports the processing and interpretation of sequencing data. Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN - Free Report). Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.